A Phase I Study of LTT462 in Patients with Advanced Cancers that Have an Altered MAPK Signaling Pathway

Full Title

A Phase I Dose Finding Study of Oral LTT462 in Adult Patients with Advanced Solid Tumors Harboring MAPK Pathway Alterations (Version date 14-JUL-2016)


MAPK is a protein signaling pathway that helps cells grow normally. Alterations in the MAPK pathway can cause cells to grow abnormally and develop into cancer. LTT462 is an investigational drug that works by blocking an abnormal MAPK pathway.

The purpose of this study is to find the highest dose of LTT462 that can be given safely in patients with advanced solid tumors that contain abnormal MAPK. LTT462 is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced solid tumor that contains at least one MAPK mutation. Examples include non-small cell lung cancer, ovarian cancer, and melanoma.
  • Patients must recover from the serious side effects of prior therapies before entering the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Gopa Iyer 646-422-4362.